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Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated
patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors
in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and
treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a
stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomy –
even incomplete – C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival.
Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A
total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment.
Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer
undergoing either immunotherapy or targeted treatment.
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Renal cell carcinoma (RCC) accounts for about 2–3% of all
malignancies (Schroeder, 1998). Due to the rareness of warning
signs, 25–30% of the patients present with metastatic disease at the
time of diagnosis (Linehan WM, 1993). The outcome of patients
with metastatic RCC (MRCC) is poor, with a 5-year survival rate of
less than 10%. In the past several years, immunotherapy consisting
of recombinant interleukin-2 (rIL-2) and recombinant interferon-
alpha (rIFN-alpha) has been considered standard first-line
treatment for patients with MRCC. Both dosage of IL-2 (Yang
et al, 2003; Upton et al, 2005) and cytokine combination vs
cytokine monotherapy (Blay et al, 1992) have been the topic of
several phase III investigations. Some authors pointed out the
benefit of high-dose IL-2 in terms of response and quality of
response (Yang et al, 2003; Upton et al, 2005), while others found
the combination of both cytokines, IL-2 and INF-alpha, crucial for
response achievement (Blay et al, 1992). However, the majority of
investigators were in complete agreement in that intravenous
cytokine administration may cause severe toxicity and should
therefore be restricted to a subset of patients with excellent
performance status. Moreover, it appeared that patient- and/or
tumour-related prognostic factors might have more impact on
survival than the choice of treatment.
Several patient- or tumour-related parameters have been
identified as prognostic factors for survival in MRCC. Among
these were nephrectomy, baseline haemoglobin, baseline lactate
dehydrogenase (LDH), C-reactive protein (CRP), alkaline phos-
phatase (aP), location and number of metastasis, performance
status, recent weight loss and neutrophil count (Neves et al, 1988;
Ljungberg et al, 1995; Citterio et al, 1997; Hoffmann et al, 1999;
Atzpodien et al, 2003; Motzer et al, 2004b). However, data from
these analyses have frequently been collected from untreated
patients. In contrast, data from 250 patients that had undergone
prior treatment for MRCC have been recently analysed for
prognosis of survival. In this analysis, Karnofsky performance
status (KPS), high corrected calcium and low haemoglobin were
found independent risk factors for survival (Motzer et al, 2004b).
The authors identified three risk groups depending on the number
of risk factors found in each patient. Patients with two or more risk
factors had a statistically significant shorter median survival (5.4
months) when compared to patients with 0 or 1 risk factor (22.1
and 11.9 months, respectively) (Motzer et al, 2004b). The
clinicopathological data in this investigation came from patients
of 29 different treatment protocols for MRCC including chemo-
therapy and/or cytokines. Fifty per cent of the patients had
received rIL-2 and/or rIFN-alpha; however, only two patients had
prior rIL-2–rIFN-alpha combination treatment.
A few years ago, we established as a standard first-line treatment
for patient with MRCC a well tolerable outpatient cytokine
combination, consisting of 2 weeks rIFN-alpha followed by 2
weeks of rIL-2, both given subcutaneously (s.c.). The aim of
this retrospective analysis is to define prognostic and predictive
factors for response and survival of patients treated according to
this regimen and to identify characteristics of responders and
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slong-term survivors. We further will discuss how this stratification
model may be relevant in the era of modern targeted agents.
PATIENTS AND METHODS
Patients
Data from 99 consecutive patients who presented with MRCC at
our department entered this analysis. All patients were treated
according to our standardised outpatient-cytokine protocol as
described below. Patients were recruited for outpatient immuno-
therapy between April 2001 and May 2005. Pretreatment
characteristics, first date of treatment, response, time to progres-
sion (TTP) and date of last follow-up or death were recorded for all
patients. Assessment of extent of disease consisted of computed
tomography scan of the chest and abdomen and/or magnetic
resonance imaging.
Methods
Treatment consisted of 4.5MUday
 1 r-IL-2, given s.c. on days 1–4
in weeks 3, 4, 8, 9, 13 and 14 and of 6MUday
 1 SC rINF-alpha on
days 1, 3, 5 in weeks 1, 2, 6, 7, 11 and 12. Treatment was performed
unless report of disease progression.
Parameters analysed for impact on prognosis consisted of
laboratory parameters, treatment-related factors, tumour-related
factors and patient-related factors:
(a) Laboratory parameters were: Haemoglobin (Hb), LDH, CRP,
aP. Haemoglobin was considered normal X11.5 for women
and X13.5 for men. As for LDH, the cutoff point for statistical
analysis was categorised 1.5 times upper limit of normal (i.e.
300Ul
 1), according to the data of Motzer et al (1999).
Alkaline phosphatase was considered normal up to 115Ul
 1.
According to the method of Hoffmann et al (1999), C-reactive
protein serum levels were divided into two groups, one group
with levels X0.8mgdl
 1, the other group with levels
o0.8mgdl
 1 (a level of o0.5mg
 1dl
 1 is considered normal).
(b) Treatment-related factors: Patients were evaluated for pallia-
tive nephrectomy, history of metastasectomy and for response
to outpatient cytokine treatment. Response and progression
were defined according to Response Evaluation Criteria in
Solid Tumours (RECIST criteria) (Duffaud and Therasse,
2000).
(c) Tumour-related factors were: Histological type of RCC (i.e.
clear-cell vs non-clear-cell type), nuclear grade, stage, time
from primary tumour to metastasis, number of metastatic sites
and metastatic locations.
(d) Patient-related factors were: Age, sex and KPS
Statistical analysis was performed using SPSS for windows
software (RE SPSS 11.0; SPSS, Chicago, IL, USA). Descriptive
statistics of relevant demographic and clinical features were
compiled. Survival time was evaluated using Kaplan–Meier
survival curves. Differences between groups were tested using
the log-rank test. Cox’s regression analysis was used for multi-
variate analysis. All predictors with the highest P-value were
excluded stepwise until only significant values were present.
Survival time was measured from the date of diagnosis of
metastasis to death or date of the latest follow-up. The time
variable for the Cox model was defined as time between the date of
metastasectomy – the latest occurring variable in our analysis –
and the time of death or latest follow-up. A two-tailed P-value
equal to or less than 0.05 was considered to indicate significance in
all tests. The Spearman rank correlation coefficient, the Kruskal–
Wallis test and the w
2 test were used to compare the variables
among the groups.
RESULTS
Patient’s characteristics
Patient’s characteristics are detailed in Table 1. A total of 99
patients (male n¼74, female n¼25, median age: 65, range: 34–82
years) were included in our analysis. The most common metastatic
location was the lung (61.4%), followed by bone (33.7%) and liver
(22.8%). Most of the patients were in good KPS (KPS 100%: 69.7%,
KPS 90%: (18.2%, KPS o80%: 12.1%). All patients had undergone
outpatient immunotherapy consisting of rIL-2 and rIFN-alpha.
The median clinical follow-up period was 2.7 years (range 6
months–16 years). The median time from diagnosis of primary
kidney tumour to diagnosis of metastasis was 3.2 months (range
0–156 months). A total of 65.7% of all patients presented with
metastatic disease at the time of diagnosis of kidney cancer.
Tumour characteristics
Eighty-five per cent of the tumours were clear-cell carcinomas and
15.2% were non-clear-cell type. A total of 38.4% of the tumours
were nuclear grade 3 and the most common local stage was pT3a
(44.4%).
Laboratory parameters
Haemoglobin was found above 11.5gdl
 1 in 79.4% of the patients.
Lactate dehydrogenase was normal in 15.2%, and CRP and aP were
found normal in 23.2% and 53.6% of the patients, respectively.
Treatment-related factors
A total of 92.9% had undergone nephrectomy and more than 50%
had one or two metastatic sites. Objective remission to rIL-
2þrIFN-alpha outpatient treatment was found in 12.8% of the
patients (8.5% complete response (CR), 4.3% partial response
(PR)), and another 35.2% experienced stable disease and 59.5%
progressed despite treatment. Patients experiencing CR, PR or SD
had a statistically significant survival benefit compared to patients
progressing on treatment (median 28 and 15 months, respectively,
P¼0.0001). Figure 1 shows differences in median survival in
dependence of response to treatment.
A total of 43.4% had undergone surgery for metastases (n¼46)
(27.3% bone, 11.1% lung, 4% central nervous system, 5% local
recurrence, 1% pancreatic lesion). Five out of 46 patients
underwent surgery for metastases twice. Table 5 outlines clinical
and histological data of patients with metastasectomy compared to
those without. No statistically significant differences could be
observed between these two groups.
Characteristics of patients with metastasectomy and surgical
techniques are detailed in Table 4. The intentions for metasta-
sectomy were pain control and/or the management of pathological
fractures (65.1%) and vital indication given by metastases to the
brain in 9.3% of the patients. In 30% of the patients, the intention
was to achieve a ‘no evidence of disease’ (NED) situation. However,
only 21% of the patients achieved NED surgically. Causes for not
achieving NED surgically (9%) were metastases to other sites
diagnosed only a few days after metastasectomy (n¼3) and
unexpected incomplete resection of metastases (n¼2). Thus,
among 46 patients undergoing metastasectomy, 80% had tumour
burden left after surgery and 90.7% presented with a KPS 480.
Metastasectomy patients were characterised in 55.8% as high-risk
patients, 37.2% presented with medium risk and 7% were in the
low-risk group. Metastasectomy was performed median 6 months
after diagnosis of primary tumour (range: 1–267 months). The
initiation of immunotherapy was median 2 months after metas-
tasectomy (range: 28 months prior to metastasectomy to 54
months after metastasectomy).
Prognostic and predictive factors in metastatic RCC
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The median overall survival was 22 months (range 1–280 months).
The following pretreatment factors were identified as univariate
predictors of poor survival:
(1) Hb level o11.5gdl
 1, (2) LDH level 4300Ul
 1, (3) CRP
X0.8mgdl
 1, (4) high nuclear grade, (5) brain metastasis, (6)
absence of nephrectomy and (7) KPSp80.
In contrast, no statistically significant differences were found for
the following parameters: time from diagnosis of primary tumour
to metastatic disease, number of metastatic sites, other metastatic
locations than brain, aP level, sex, age, stage and histological type
of RCC.
Four factors were found to be significant in the multivariate
analysis. As shown in Table 2, the major prognostic factor is
nuclear grade (P¼0.003, hazard ratio 3.923), followed by
metastasectomy (even incomplete) (P¼0.01, hazard ratio 0.297;
Figure 1), CRP (P¼0.034, hazard ratio 2.721) and serum LDH
(P¼0.035, hazard ratio 3.037). According to the number of
multivariate risk factors, we established three risk groups and each
patient was assigned to a specific risk group: low risk (zero risk
factors), medium risk (one or two risk factor) and high risk (three
or more risk factors).
There was a statistically significant difference in survival
between patients in the low- (Po0.001), medium- and high-risk
groups: 30.53 months (range: 6.4–280), 22.1 months (range: 0.43–
67) and 5.9 months (range: 1–39 months), respectively (Figure 2).
Response to immunotherapy
When comparing the three risk groups for response to treatment,
we found statistically significant differences: among the patients
responding to treatment, 66.7% were low, 33.3% medium risk, but
no patient in the high-risk group responded to treatment (Table 3).
Table 1 Clinicopathological data of 99 patients with MRCC
Characteristics n Median % Range
No. of patients 99
Sex
Male 74 74.7
Female 25 25.3
Age (years) 65 34–83
KPS
100% 69 69.7
90% 18 18.2
p80% 12 12.1
Histology
Clear cell 85 85.9
Papillary 12 12.1
Collecting duct 2 2
T stage
pT1 15 15.2
pT2 12 12.1
pT3a 44 44.4
pT3b 28 28.3
Nuclear grade
G1 3 3
G2 30 30.3
G3 38 38.4
G4 18 18.2
Not available 10 10.1
Nephrectomy
Yes 92 92.9
No 7 7.1
No. of metastatic sites
Local recurrence only 3 3
1 site 33 33.3
2 sites 28 28.3
3 sites 17 17.2
X4 sites 18 18.2
Sites of metastatic disease
Lung 62 61.4
Mediastinum 19 18.8
Bone 34 33.7
Liver 23 22.8
Abdominal lymph nodes 14 18.9
Pancreas 2 2
Cerebral 11 10.9
Surgery for metastases
No metastasectomy 56 56.6
Metastasectomy 43 43.4
Pulmonary 11 11.1
Bone 27 27.3
Local recurrence surgery 5 5
CNS 4 4
Pancreas 1 1
Patients receiving metastasectomy twice 5 5
Baseline laboratory parameters
Haemoglobin normal X11.5g/dl 78 12.5 78.8 8.8–16.3
LDH normal o200U/l 68 176 68.7 26–2350
CRP normal o0.5mg/dl 23 2.1 23.2 0.5–195
aP normal 0–15U/l 53 111 53.5 47–819
Best response to outpatient immunotherapy
CR 8 8.5
PR 4 4.3
SD 33 35.2
Table 1 (Continued)
Characteristics n Median % Range
PD 49 49.5
Not evaluable 5 5.1
aP¼alkaline phosphatase; CNS¼central nervous system; CR¼complete response;
CRP¼C-reactive protein; KPS¼Karnofsky performance status; LDH¼lactate
dehydrogenase; MRCC¼metastatic renal cell carcinoma; PD¼progressive disease;
PR¼partial response; SD¼stable disease.
Overall survival
Kaplan − Meier estimates
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Figure 1 Overall survival for the independent risk factor metastasectomy
(log rank P¼0.026, median overall survival 27.2 vs 20.6 months).
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24.5% medium risk and 18.4% low risk (P¼0.001).
In addition, baseline Hb levels o11.5mgdl
 1 (P¼0.021) and
histology of non-clear-cell carcinoma (P¼0.024) were unfavour-
able predictors for response. All patients with objective remissions
and 97% of the patients achieving SD had baseline Hb levels of
greater than 11.5mgdl
 1.
TTP
Median TTP and median progression-free survival (PFS) were 6.55
months, respectively. Two factors were independent factors for
time to tumour progression: high KPS and Hb levels greater than
11.5mgdl
 1. Patients with Hb levels lower than 11.5mgdl
 1 had a
statistically significant shorter TTP (8.29 months) than patients
with Hb levels higher than 11.5mgdl
 1 (3.22 months) (P¼0.0013).
DISCUSSION
The aim of this analysis was to define prognostic factors for
response to treatment and survival in patients treated with an
outpatient-cytokine regimen for MRCC. We identified nuclear
grade, surgery for metastases, CRP and LDH as independent risk
factors for survival. Moreover, we found statistically significant
survival differences between three established (Motzer et al,
2004a,b) risk groups (30.5, 22 and 5.9 months, respectively,
P¼0.001).
Remarkably, metastasectomy was an independent prognostic
factor for survival. The benefit of surgery has frequently been
demonstrated in the past, particularly in cases of singular lung
metastasis with achievement of a ‘NED’ situation (van der Poel
et al, 1999; Hofmann et al, 2005). However, in our analysis, only
10% of the patients who had undergone metastasectomy had NED
after resection. One could argue that survival differences between
metastasectomy and nonmetastasectomy patients are the result of
patient selection, considering only patients with excellent perfor-
mance status for this procedure. However, the intention for
metastasectomy was rarely based on oncological consideration,
that is, reduction of tumour burden, but was rather driven by a
suddenly occurring necessity, that is patients presenting with
pathological fractures from bone metastases. As shown in Table 5,
the most common indication for metastasectomy was maintenance
of the musculoskeletal system integrity or higher pain control
(65.1%). Another indication (9.3%) was the resection of metastases
to the brain otherwise causing increased intracranial pressure.
Only in 30% the intention for metastasectomy was to achieve NED,
which finally has been achieved in 21% only. As shown in Tables 4
and 5, the majority of our patients were in good KPS (480%) and
patients with lower KPS than 80% were found in both the
metastasectomy group and the nonmetastasectomy group. Thus,
we postulate that metastasectomy – even if NED is not achieved
surgically – is a powerful prognostic factor in MRCC. In an attempt
to explain these finding, a series of factors were considered:
High CRP is caused by excessive IL-6 production, a multi-
functional cytokine with growth factor function in RCC (18). IL-6
was shown to correlate with stage, nuclear grade and proliferation
index (Costes et al, 1997). By investigating which patients mostly
benefit from palliative nephrectomy, Fujikawa and co-workers
found that particularly those presenting with elevated pretreat-
ment serum CRP levels had a benefit from nephrectomy (Matsui
et al, 2001). Although these findings concern the removal of the
primary tumour, one can hypothesise that debulking of both the
primary tumour or metastatic lesions may – after a short
postoperative increase – finally lower the serum level of acute
phase reactants, thus lowering disease progression.
Numerous stratification models for MRCC survival have been
defined in the past, with KPS, CRP, nephrectomy, Hb and nuclear
grade being the most frequently identified risk factors. To date,
several investigators favour the risk stratification model proposed
by Motzer et al (2004b) with corrected calcium, haemoglobin and
PFS as independent prognostic factors for survival. In this model,
three risk groups with statistically significant survival differences
have been described (22, 11.9 and 5.4 months, respectively). An
interesting finding is that low-risk patients in our analysis had a
considerable better median survival than patients of Motzer’s low-
risk group (30.5 vs 22 months, respectively). Motzer et al (2004b)
had observed that compared to patients treated after 1990, patients
treated earlier were more often categorised as high risk. We believe
Table 2 Multivariate survival analysis of pretreatment clinical factors
Risk factors Categories compared P-value Risk ratio 95% CI
Grade G1/G2 vs G3/G4 0.003 3.923 1.608–9.573
CRP o0.8 vs X0.8mgdl
 1 0.034 2.721 1.080–6.858
Metastasectomy Yes vs no 0.010 0.297 0.118–0.749
LDH o300 vs 4300Ul
 1 0.035 3.037 1.080–8.540
CI¼confidence interval; CRP¼C-reactive protein; LDH¼lactate dehydrogenase.
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Figure 2 Overall survival stratified according to risk group (log rank
Po0.001 for low vs medium risk and Po0.001 for medium vs high risk,
median overall survival: 30.53 vs 22.1 vs 5.9 months).
Table 3 Response to immunotherapy stratified according to risk group
(P¼0.001)
CR, PR SD PD
n % n % n %
Low risk, n¼32 8 66.7 15 46.9 9 18.4
Medium, risk n¼32 4 33.3 16 50.0 12 24.5
High risk, n¼29 0 0 1 3.1 28 57.1
CR¼complete relapse; PD¼progressive disease; PR¼partial relapse; SD¼stable
disease.
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Patient
Metastasectomy
(location and surgical
techniques)
Intention of
metastasectomy
Tumour burden
left after
metastasectomy
(other sites)
Time to tumour
progression after
complete
metastasectomy KPS
Risk
group
Time between
diagnosis and
metastasectomy
(months)
Time between
metastasectomy and
immunotherapy
(months)
1 Bone (hip: resection and
reconstruction)
Fracture,
pain control
Bone 90 Medium 60.79 1.55
2 Bone (curretage and
vertebroplasty)
Fracture,
pain control
Bone 90 Medium 15.63 2.01
3 Bone (humerus: curretage
and plate osteosynthesis)
Fracture,
pain control
Liver, lung,
mediastinal lymph
Nodes
100 High 0.59 2.6
4 Bone (2 curretages and
vertebroplasties)
Pain control Liver 100 Medium 1.61 0.86
5 Bone (humerus: curretage
and plate osteosynthesis)
Fracture,
pain control
Liver, lung 100 Medium 13.2  11.2
6 Bone (curretage and
vertebroplasty)
Pain control Liver 100 Medium 98.52 1.84
7 Lung (segment resection),
bone (hip: resection and
reconstruction)
Tumour reduction No 4.3 90 Low 0 0.56
8 Lung (segment resection) Tumour reduction No 9.4 100 High 267.40 0.92
9 Pancreas (whipple operation) Tumour reduction No 46 100 Medium 0 46.25
10 Bone (curretage and
vertebroplasty)
Pain control Lung 100 Medium 16.41 3.05
11 Bone (humerus: curretage
and plate osteosynthesis)
Fracture, pain
control
Bone 100 High 65.53 1.15
12 Bone (femur: curretage
and osteosynthesis)
Fracture, pain
control
Lung 90 High 0 2.1
13 Lung (segment resection) Tumour reduction/
others
a
Abdominal lymph
nodes
100 High 0 1.74
14 Bone (femur, acetabulum:
curretage and
osteosynthesis)
Fracture, pain
control
Lung 90 High 51.09 3.18
15 CNS (excision), lung
(segment resection)
Vital indication No 2 100 Medium 33.78 2.47
16 Local recurrence
(tumour debulking)
Pain control No 6 100 High 93.16 12.01
17 Bone (curretage and
vertebroplasty)
Fracture, pain
control
Bone 100 Medium 12.93  13.08
18 Bone (hip: excision and
reconstruction)
Fracture, pain
control
Adrenal 80 High 0 2.3
19 CNS (excision) Vital indication Lung, bone 100 High 35.13 14.97
20 Local recurrence
(tumour debulking)
Pain control Regional tumour
mass
100 Medium 48.06  28.32
21 Bone (femur: curretage
and osteosynthesis)
Fracture, pain
control
Bone 100 Low 0 2.92
22 Lung (excision of pleural
metastasis)
Tumour reduction No 50.2 100 Medium 96.12 53.91
23 Bone (hip: excision and
reconstruction)
Fracture, pain
control
Lung 80 High 0.95  0.33
24 CNS (excision) Tumour reduction Lung 100 High 110.13  4.38
25 Bone (hip: excision and
reconstruction)
Fracture, pain
control
Lung 100 High 0.49 0.72
26 Lung (segment resection) Tumour reduction No 9.2 100 High 6.05  5.66
27 Local recurrence
(tumour debulking)
Pain control Lung 100 Low 121.12 23.52
28 CNS (excision) Vital indication Lung 100 High 46.05  22.83
29 Bone (femur: curretage and
osteosynthesis)
Fracture, pain
control
Bone 100 High  5.23 6.64
30 Bone (femur: curretage and
osteosynthesis)
Fracture, pain
control
Lung 80 Medium  7.04 18.75
31 Lung (segment resection) Tumour reduction/
others
b
Lung 100 High 90.16  14.97
32 Bone (curretage and
vertebroplasty)
Pain control Bone 90 High 60.10 24.21
33 Bone (hip: excision and
reconstruction)
Pain control Lung 100 High 127.80 4.38
34 Bone (hip: excision and
reconstruction)
Pain control Lung 90 High 73.09  7.27
35 Lung (segment resection) Tumour
reduction/
others
a
Liver 90 High 0 2.37
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decades may be explained by both an improvement in surgical
techniques for metastases and the advent of supportive care
measures, for example, the erythropoietins.
In contrast to numerous prognostic factors, only two predictive
factors for response to treatment have been identified yet: the
proliferation status in terms of Ki-S5-immunoreactive scores
(Papadopoulos et al, 1996) and the histological type of RCC
(Upton et al, 2005). IL-2 responsiveness was shown to be predicted
by clear-cell type, presence of more than 50% alveolar features and
absence of papillary or granular features. In accordance with these
findings, we found clear-cell histology as predictive for response to
our treatment. Moreover, we could identify Hb as an independent
predictor of response, which might be associated with high levels
of circulating vascular endothelial growth factor (VEGF) in
anaemic MRCC patients. In MRCC, erythropoietins were shown
to be important for both supportive care and immunomodulatory
effects: high levels of VEGF have been found in anaemic patients
progressing on IL-2 treatment (Lissoni et al, 2001). Retreatment of
the very same patients with IL-2 and erythropoietin not only
Table 4 (Continued)
Patient
Metastasectomy
(location and surgical
techniques)
Intention of
metastasectomy
Tumour burden
left after
metastasectomy
(other sites)
Time to tumour
progression after
complete
metastasectomy KPS
Risk
group
Time between
diagnosis and
metastasectomy
(months)
Time between
metastasectomy and
immunotherapy
(months)
36 Bone (hip: excision and
reconstruction)
Fracture, pain control Bone 90 High 0 2.56
37 Local recurrence Pain control Bone 100 High 132.24 1.61
38 Lung (segment resection) Tumour
reduction/others
a
Bone, lung 90 Medium  0.89 1.35
39 Bone (humerus: curretage
and plate osteosynthesis)
Fracture,
pain control
Liver 100 Medium  4.38 6.35
40 Bone (femur: curretage
and osteosynthesis)
Fracture,
pain control
Lung 100 Medium  0.43 1.88
41 Bone (curretage
and vertebroplasty)
Pain control Liver 80 Medium 33.95 19.11
42 Bone (hip: excision
and reconstruction),
lung (segment resection)
Tumour reduction,
pain control
No 7 100 High 120.86 7.53
43 Local recurrence
(tumour debulking),
lung (lobectomy)
Tumour reduction No 14.5 100 High 102.01  5.8
Total Bone: 27.3%
Lung: 11.1%
CNS: 4%
Local recurrence: 5%
Pancreatic lesion: 1%
Metastasectomy twice: 5%
Total: 43.3%
Pain control/
fracture: 65.1%
Vital indication: 9.3%
Tumour reduction:
27%
Other sites left: 79%
NED: 21%
Median: 9.2
Months range:
2–50.2
480%:
90.7%
p80%:
9.3%
Low risk:
7%
Medium
risk:
37.2%
High risk:
55.8%
Median time:
6 months after
diagnosis
Range: 1–267
months
Median time: 2 months
after metastasectomy
Range: 28 months
prior – 54 months
after metastasectomy
CNS¼central nervous system; KPS¼Karnofsky performance status.
aMetastases to other sites were diagnosed only a few days after metastasectomy.
bUnexpected incomplete
resection of the metastases.
Table 5 Comparison of characteristics of patients with metastasectomy and patients without metastasectomy
Characteristics Metastasectomy (n¼43) No metastasectomy (n¼56) v
2 test
KPS
100% 29 (67.4%) 40 (71.4%) P¼0.357
90% 10 (23.3%) 8 (14.3%)
p80% 4 (9.3%) 8 (14.3%)
Haemoglobin normal X11.5gdl
 1 35 (81.4%) 43 (76.8%) P¼0.519
LDH cutoff o300Ul
 1 37 (86%) 44 (78.6%) P¼0.685
CRP o8mgdl
 1 18 (41.9%) 23 (41.1%) P¼0.471
Risk groups
Low risk 3 (7%) 29 (51.8%)
Medium risk 16 (37.2%) 16 (28.6%)
High risk 24 (55.8%) 5 (8.9%)
Histology
Clear cell 40 (93%) 45 (80.3%)
Papillary 3 (7%) 9 (16.1%)
Collecting duct 0 2 (3.6%) P¼0.173
CRP¼C-reactive protein; KPS¼Karnofsky performance status.
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slowered VEGF levels but also restored responsiveness to IL-2 in
terms of achieving at least stable disease (Lissoni et al, 2001).
Another predictive marker for response that could be identified in
our analysis was the risk group affiliation. We found more
responders in the low-risk group (66.7%) than in the medium-risk
group and no responder in the high-risk group. Accordingly, we
characterise a responder by low nuclear grade, low CRP,
metastasectomy and low LDH. Particularly, CRP (and IL-6) levels
have often been found to impair IL-2 efficacy (Blay et al, 1992;
Simpson et al, 1995; Tartour et al, 1996; Thiounn et al, 1997). The
mechanism by which these acute phase reactants interfere with IL-
2-induced tumour regression is not defined. Some authors
hypothesised that soluble CRP prevents recognition and binding
of tumour cells by IL-2-activated effector cells (Kedar et al, 2004).
The question arises whether our prognostic and predictive
model, established from patients undergoing cytokine treatment,
may be relevant in the era of targeted therapies (Ratain, 2004;
Yang, 2004; Hainsworth et al, 2005; Motzer et al, 2006). Although
these agents have shown promising results in MRCC, it is
questionable whether they will completely replace established
strategies. It appears that their full potential may rather be
achieved by combination with other agents (i.e. other targeted
therapies, immunotherapy) or by combination with surgery, that
is, metastasectomy. Moreover, our predictive model may offer
uncommon therapeutical considerations. Prediction of response to
treatment by CRP may not be restricted to immunotherapy: acute
phase reactants were shown to raise plasma levels of alpha 1 acid
glycoprotein, a protein that has been associated with resistance to
anti-epidermal growth factor receptor (EGFR) agents (Viloria-Petit
et al, 2001). MRCC was shown to be resistant to anti-EGFR
treatment (Motzer et al, 2003). We hypothesise that a therapeutical
reduction of CRP levels either by metastasectomy or glucocorti-
coids – which have been shown to inhibit VEGF-mRNA – may
circumvent acute phase reactants-induced drug resistance. This
phenomenon might be of particular interest when using agents
that inhibit both the VEGF and EGFR signalling cascade (i.e.
Sorafenib). Thus, a multimodal treatment approach that considers
CRP reduction may possibly increase the efficacy of new agents.
In summary, the information gained through our prognostic
and predictive model appear particularly relevant for both patients
undergoing immunotherapy and patients intended for new
targeted agents. It may allow an individualised treatment and the
circumvention of drug resistance. However, independently from
the systemical treatment approach, our data strongly suggest that
even incomplete reduction of tumour burden may confer a
survival benefit in MRCC. Thus, we highly emphasise a strong
cooperation with surgeons in this disease. As the majority of
patients (with or without metastasectomy) in this analysis had a
favourable KPS, a careful patient selection for any surgical
procedure seems warranted at this stage of the disease.
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